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Abstract Oxidative stress has been described as important to
Huntington disease (HD) progression. In a previous HD study,
we identified several carbonylated proteins, including pyri-
doxal kinase and antiquitin, both of which are involved in
the metabolism of pyridoxal 5´-phosphate (PLP), the active
form of vitamin B6. In the present study, pyridoxal kinase
levels were quantified and showed to be decreased both in
HD patients and a R6/1 mouse model, compared to control
samples. A metabolomic analysis was used to analyze metab-
olites in brain samples of HD patients and R6/1 mice, com-
pared to control samples using mass spectrometry. This tech-
nique allowed detection of increased concentrations of pyri-
doxal, the substrate of pyridoxal kinase. In addition, PLP, the
product of the reaction, was decreased in striatum from R6/1
mice. Furthermore, glutamate and cystathionine, both sub-
strates of PLP-dependent enzymes were increased in HD.
This reinforces the hypothesis that PLP synthesis is impaired,
and could explain some alterations observed in the disease.
Together, these results identify PLP as a potential therapeutic
agent.
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Abbreviations
ALDH7A1 α-aminoadipic semialdehyde dehydrogenase or
antiquitin
GSH Reduced glutathione
HD Huntington disease
Htt Huntingtin protein
mHtt Mutant huntingtin
LC Liquid chromatography
MOPS 3-(N-Morpholino)propanesulfonic acid
MS Mass spectrometry
PDXK Pyridoxal kinase
PLP Pyridoxal 5´-phosphate
TOF Time of flight
Introduction
Huntington disease (HD) is a dominantly inherited neurode-
generative disease caused by the expansion of CAG trinucle-
otide repeats in exon 1 of the huntingtin gene that encodes a
stretch of polyglutamines (polyQ) in the huntingtin (Htt) pro-
tein (Group 1993). The disease appears when the number of
glutamines exceeds 40. Age of onset and disease severity are
strongly correlated with the length of the CAG expansion
(Benitez et al. 1994). Clinical symptoms include psychiatric
and cognitive abnormalities, as well as involuntary move-
ments (chorea). With HD progression, motor rigidity, depres-
sion, and dementia predominate, and inevitably lead to death.
Anatomically, HD is characterized by progressive brain atro-
phy, affecting predominantly the striatum, and the cortex to a
lesser extent (Reiner et al. 1988). Htt is a widely expressed
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350-kDa protein that has been described to be related to sev-
eral roles, however, its function is still unknown. One of the
most significant findings in HD neuropathology was the pres-
ence of mutant Htt (mHtt) deposits, mostly in striatum and
cortex (DiFiglia et al. 1997). Although the presence of aggre-
gates often correlates with toxicity (Perutz 1999), it has been
described that the oligomeric species, formed before the con-
stitution of the mature mHtt deposits, are highly toxic and
responsible for the cellular alterations observed in HD
(Arrasate et al. 2004). Increasing evidence supports the in-
volvement of mitochondria in HD pathogenesis. Impaired en-
ergy metabolism leading to ATP depletion, due to functional
defects in mitochondrial complexes (Jenkins et al. 1993;
Shirendeb et al. 2011) suggest that defective mitochondria
may be responsible for neuronal damage in HD. Such mito-
chondrial damage might generate an oxidative stress situation
well described in HD (Dugan et al. 1995; Browne 2008;
Sorolla et al. 2008). Thus, cellular dysfunction in HD has been
related to loss of normal physiological function and especially
to gain of toxic function of mHtt.
In previous publications using proteomic techniques
(Sorolla et al. 2008; Sorolla et al. 2010), we demonstrated in
human HD samples and also in a mouse model that several
enzymes were oxidized (carbonylated) in striatum. These re-
sults pointed to a possible disturbance in the metabolism of
pyridoxal 5´-phosphate (PLP), the active form of vitamin B6.
Two enzymes, pyridoxal kinase (PDXK) and antiquitin 1,
were identified as carbonylated proteins in human HD and
the conditional HD mouse model Tet/HD94 (Sorolla et al.
2010). PDXK phosphorylates pyridoxal generating PLP.
Antiquitin 1, encoded by the ALDH7A1 gene, acts as a δ-1-
piperideine-6-carboxylate dehydrogenase or α-aminoadipic
semialdehyde dehydrogenase. Mutations in the ALDH7A1
gene cause pyridoxine-dependent seizures, a disease affecting
newborns and children. In these cases, mutations abolish
antiquitin 1 activity and the accumulating substrate,
piperideine-6-carboxylate, inactivates PLP by forming a
Knoevenagel condensation product (Mills et al. 2006). The
lack of PLP causes seizures and is associated with learning
difficulties. These seizures are fully controlled by pyridoxine
(Rankin et al. 2007). Thus, antiquitin 1 oxidation observed in
HD could result in its inactivation, exacerbating the lack of
PLP available as a cofactor. The active form of vitamin B6 is a
necessary cofactor in more than 140 distinct enzymatic activ-
ities catalogued by the Enzyme Commission (http://www.
chem.qmul.ac.uk/iubmb/enzyme/). To study whether such
enzymes might be affected in HD, the substrate of two key
PLP-dependent enzymes, glutamate and cystathionine, were
analyzed. They are involved in the synthesis of GABA, a
neurotransmitter described to be decreased in striatal neurons
of HD patients and, ii) synthesis of glutathione (GSH), a key
molecule maintaining the cellular redox status and the GSH-
dependent antioxidant defense system.
In the present study, we investigated the hypothesis that
metabolic changes resulting from oxidation of PDXK and
antiquitin are involved in HD pathogenesis due to decreased
PLP levels. We report decreased levels of PDXK, both in HD
patients and R6/1 transgenic mice. Using LC-MS metabolo-
mics several metabolites were quantified giving support to an
impaired PLP synthesis and, as a consequence, an altered
PLP-dependent metabolism in HD. The biological signifi-
cance in HD pathology is discussed.
Material and methods
Human samples
Human brain tissues (striatum and cortex) were obtained from
the Institute of Neuropathology and University of Barcelona
Brain Banks (Barcelona, Spain), following the guidelines of
the local ethics committees. Control cases had not suffered
neurologic or psychiatric disease and the neuropathology ex-
amination was strictly normal, including lack of Alzheimer
disease-associated changes. Eight HD cases (range 41–62
CAG repeats) and eight controls were analyzed (Table 1).
Control and HD groups were balanced for age, sex and post-
mortem time, excluding these parameters as potential differ-
ences between these groups. After neurological examination,
all HD cases were classified as stage 4 according to Vonsattel
et al. (1985). All procedures were carried out according to the
Helsinki declaration and conducted according to the guide-
lines of the European Community Council.
Table 1 Summary of controls (C) and HD (H) cases
Patient Sex Age Postmortem delay (h)
C1 Female 73 7
C2 Female 73 5.5
C3 Male 51 4
C4 Female 24 6
C5 Male 70 13
C6 Female 47 9.6
C7 Male 53 3
C8 Male 46 15
H1 Female 72 7
H2 Female 72 5
H3 Male 68 4
H4 Female 28 4.2
H5 Male 71 10.2
H6 Female 65 15.2
H7 Male 59 5.5
H8 Male 60 13.1
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Murine samples
Murine brain tissues (striatum, cortex and cerebellum) were
obtained from wild-type (WT) and R6/1 transgenic mice for
the human exon-1-Htt gene (CAG repeats: 168–189), all of
them in B6CBAF1/J background (Mangiarini et al. 1996).
Either 3-month-old (n = 7, each group) and 7-month-old
(n = 4, each group) mice were bred at Severo Ochoa Center
(Madrid). Procedures using laboratory animals were in accor-
dance with the European Union Directives and institutional
guidelines approved by the research ethics committee of
Consejo Superior de Investigaciones Científicas (CSIC). All
efforts were made to minimize the number of animals used
and the suffering involved. Mice were maintained in a
temperature-controlled environment on a 12-h light/dark cycle
with food and water ad libitum.
Sample preparation
To perform Western blot analysis, brain tissue was homoge-
nized as described (Sorolla et al. 2010). Tissue extracts were
separated by SDS–PAGE and transferred to polyvinylidene
difluoride membranes. The following antibodies were used:
anti-PDXK (Santa Cruz Biotechnology; Ref. sc-67,361), anti-
antiquitin (Santa Cruz Biotechnology; Ref. SC79399), and
anti-actin (Sigma; Ref. A1978). Images from Western blots
were captured using a Chemidoc XRS system (BioRad) and
band intensities were quantified by Quantity One software
(BioRad). In metabolomic studies, brain tissue (10 mg) was
homogenized in a 200 μl buffer containing 1 mM MOPS,
1 8 0 mM KC l , a n d 2 mM EDTA , p l u s 1 mM
diethylenetriaminepentaacetic acid (DTPAC) as reductant
and 1 μM butylated hydroxytoluene (BHT) as antioxidant.
The protein was precipitated with cold methanol and incuba-
tion for 60 min at −20 °C. The sample was centrifuged at 12,
000×g for 5 min to remove protein. The supernatant was dried
in a vacuum centrifuge (Speed-Vac), resuspended in 100 μl
water and filtered using microcentrifuge filters.
Data acquisition and analysis
The system used was an HPLC 1200 series coupled to an ESI-
Q-TOF - MS/MS 6520 (Agilent Technologies). The
deproteinized extract (4 μl) was applied to a reverse phase
column (C18 Luna 3n pfp(2) 100 Å 150x2mm,
Phenomenex). The flow rate was 200 μL/min. Solvent A
was composed of water containing 0.1 % formic acid.
Solvent B was composed of 95 % acetonitrile and 5 % water
containing 0.1 % formic acid. A 20-min linear gradient rang-
ing from 5 to 100 % solvent B was performed. Data were
collected in positive electrospray mode TOF (time of flight),
operated in full-scan mode at 100 to 3000 m/z in an extended
dynamic range (2 GHz), using N2 as the nebulizer gas (5 L/
min, 350 °C). The capillary voltage was 3500 V with a scan
rate of 1 scan/s.
Data Analysis and Quantitative Analysis of metabolites
were performed using Masshunter Software (Agilent
Technologies). The m/z values used for quantification were
m/z 150.056 [M + H]+ − [H2O] for pyridoxal, m/z 130.0503
[M + H]+ − [H2O] for glutamate, and m/z 223.074 [M + H]+
for cystathionine. Identities were confirmed using an orthog-
onal characterization (based on exact mass <10 ppm and on
retention time) and MS/MS spectrum, compared with authen-
tic standards (Jové et al. 2011). Data are presented as means ±
standard error from at least three independent experiments.
Statistical analysis was performed using the non-parametric
Mann-Whitney test.
Results and discussion
Metabolic disturbances in pyridoxal metabolism
in human HD
Oxidative stress seems to play an important role in HD. In this
context, we demonstrated that two enzymes involved in the
metabolism of PLP (pyridoxal kinase and antiquitin 1) were
oxidized in human HD and also in an HD mouse model
(Sorolla et al. 2010). To decipher whether such oxidation
may have physiological consequences, we analyzed levels of
PDXK in human HD brain samples. Western blot performed
with anti-PDXK showed around a 30 % decrease in both
striatal (Sorolla et al. 2010) and cortex HD human samples
compared to controls (Fig. 1). Decreased levels of PDXK
were not unexpected, because it is known that protein oxida-
tion labels them for degradation. PDXK catalyzes pyridoxal
phosphorylation and can also phosphorylate both pyridoxine
and pyridoxamine, which are further converted to PLP. Thus,
PLP synthesis could be impaired both by the decrease in
PDXK levels and by its increased oxidation. Antiquitin 1 ox-
idation observed in HD could result in its inactivation, exac-
erbating the lack of PLP available as a cofactor. Unfortunately,
antiquitin 1 levels could not be detected with confidence by
the antibody.
To delve deeper into the effects of PDXK alteration, we
used a directed metabolomic approach to analyze whether
such PLP deficiency could be detected from ametabolite point
of view. Pyridoxal (the substrate of PDXK) appeared clearly
identified in the chromatographic separation and its relative
quantity was increased in HD human brain (both in cortex and
striatum), compared to control subjects (Fig. 2). PLP, the prod-
uct of the reaction catalyzed by PDXK, could not be detected
with confidence probably due to the low levels of PLP com-
pared to pyridoxal (a ratio between 1/5 and 1/10) and more
important, to the effect of phosphatases postmortem.
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Metabolic disturbances in pyridoxal metabolism in R6/1
mice
Similarly to human results, striatum and cortex samples from
7-month-old R6/1 mice showed decreased levels of PDXK
(Fig. 3). When samples from 3-month old mice were ana-
lyzed, PDXK also presented lower levels in cortex, but not
in striatum (Fig. 3). Cerebellum, a brain area minimally affect-
ed by the disease did not show significant differences between
R6/1 and control animals (Fig. 3).
Pyridoxal levels were determined in mice samples and sim-
ilar results from those in humans were obtained in striatum
and cortex samples from both 3-month-old and 7-month-old
R6/1 mice compared to controls (Fig. 4a). Differences were
not detected in mouse cerebellum, a brain area not affected by
the disease (Fig. 4a). Interestingly, pyridoxal levels were in-
creased as early as 3-month-old R6/1 mice compared to con-
trols. PLP levels were significantly reduced in striatum from
7-month-old R6/1mice compared to control animals (Fig. 4b).
Striatum is the most affected tissue in HD, and 7 month-old
animals are in an advanced disease progression stage. Lack of
significant differences in cortical PLP levels could be ex-
plained by the fact that this area is less affected than striatum
in HD. At 3 month-old, PLP levels did not change (Fig. 4b); at
this time motor coordination measured by the rotarod perfor-
mance test was affected but less than at 7-month-old R6/1
mice (not shown). Alteration of pyridoxal levels together with
decreased levels of PDXK occurring at early time (3-month-
old R6/1 mice) might be primary disturbances in pathogene-
sis, triggering a decrease in PLP levels in a later stage, when
motor coordination is affected. All these evidences suggest
that primarly impaired pyridoxal metabolim leads finally to
PLP deficiency in striatum, a motor control area, which might
act as an event for motor disturbances in HD.
Glutamate and cystathionine are increased in HD
PLP deficiency in HD might affect glutamate decarboxylase
(GAD), a PLP-dependent enzyme. It has been postulated that
GAD activity is regulated by a cycle of activation and inacti-
vation by the binding or realease of its cofactor (Battaglioli
et al. 2003) and GAD activity is compromised in vivo by
diminished levels of PLP in rat forebrain homogenates in an
age dependent manner (Massieu et al. 1994). Such impairment
Fig. 1 Levels of PDXK in humans. Western blot analysis against PDXK
of tissue extracts were performed. HD (HD) patients and controls (C)
samples of human striatum and cortex. Actin was used as a loading
control. Bands from the Western blots were quantified and the relative
intensities calculated for controls (grey bar) and HD (black bar). The data
is represented as amean relative intensity ± SE. *p < 0.05. Striatumdata is
reprinted from Free Radical Biology & Medicine, 49, Sorolla MA,
Rodríguez-Colman MJ, Tamarit J, Ortega Z, Lucas JJ, Ferrer I, Ros J
and Cabiscol E. Protein oxidation in Huntington disease affects energy
production and vitamin B6 metabolism, 612–621, 2010, with permission
from Elsevier
Fig. 2 Levels of pyridoxal in humans. Brain samples were processed and
compared with authentic standard. Pyridoxal was quantified in control
and HD samples of human striatum and cortex. The data is represented as
a mean relative intensity ± SE. *p < 0.05
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in catalytic activity of glutamate decarboxylase would result
in increased levels of glutamate and decreased levels of
GABA, the product of the reaction. In humans, glutamate
levels presented a high variability between individuals,
precluding the observation of any statistically significant dif-
ferences between HD and controls (not shown). In mice, glu-
tamate was clearly identified as being increased in all 3 studied
tissues from 7-month-old R6/1 mice compared to WT
Fig. 3 Levels of PDXK in mice.
Western blot analysis against
PDXK of tissue extracts were
performed. WT (C) and R6/1 (H)
mice from striatum, cortex, and
cerebellum areas (3M: 3-months-
old mice; 7M: 7-month-old mice).
Actin was used as a loading
control. Bands from the Western
blots were quantified and the
relative intensities calculated for
controls (grey bar) and HD (black
bar). The data is represented as a
mean relative intensity ± SE.
*p < 0.05
Fig. 4 Levels of pyridoxal and
PLP in mice: a Pyridoxal, and b
PLP were quantified in WT and
R6/1 mice from striatum, cortex,
and cerebellum areas (3M: 3-
month-old mice; 7M: 7-month-
old mice). The data is represented
as a mean relative intensity ± SE.
*p < 0.05
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(Fig. 5a). Increases in glutamate levels were only statisti-
cal significant in striatum and cortex and greater in these
tissues than in cerebellum. In 3-month-old mice, although
glutamate levels were slightly higher in R6/1 mice, no
statistically significant differences were detected (not
shown). Such observations are in agreement with the pro-
posal that an excess of glutamate is the mechanism for
cell death in the excitotoxic model of HD, especially in
striatum (Tabrizi et al. 1999; Anitha et al. 2011). GABA
levels could not be detected in our samples. Nevertheless,
in human postmortem HD studies, the concentration of
this neurotransmitter in HD has been described to be re-
duced to less than one-third of normal values in the stri-
atum (Perry et al. 1973), with deficits exceeding 25 % in
the cortex (Reynolds and Pearson 1987). Similarly,
striatum-specific lower concentrations of GABA are de-
scribed in the R6/1 mouse model (Tsang et al. 2006) and
in rats (Tsang et al. 2009). These results are important
since striatal neurodegeneration is reflected by intrinsic
neuron deficiency in the neurotransmitters, particularly
in GABA. Our results may explain why 2 years of
glutamate administration in HD patients (the substrate
for glutamate decarboxylase) and pyridoxine did not
improve motor and behavioral function (Barr et al.
1978). Therefore, we would hypothesize that pyridoxine
administration was not efficiently converted to PLP
due to PDXK deficiency and that decreased PLP
availability would inhibit GABA production by glutamate
decarboxylase.
Glutathione metabolism might also be affected by PLP-
deficiency. Cystathionine is converted to cysteine (a precursor
of glutathione) by cystathionine gamma-ligase, which uses
PLP as a cofactor. In humans, cystathionine levels did not
show statistically significant differences between HD and con-
trols due to high individual variability (not shown). However,
cystathionine levels were highly increased in all three 7-
month-old R6/1 tissues compared to control animals
(Fig. 5b), which could be due to a deficit in cystathionine
gamma ligase activity. Cystathionine could not be detected
in young mice. According to our hypothesis, lower levels of
PLP would also affect GSH synthesis and, as a consequence,
the entire GSH-dependent antioxidant defense system.
However, we found no significant differences in GSH levels
either in human or in mouse samples (not shown). Published
results are not conclusive. Altered glutathione metabolism
was described using metabolomic approaches in 3-
nitropropionic treated rats (Chang et al. 2011). In HD patients,
lower levels of reduced GSH were detected both in plasma
(Klepac et al. 2007) and in red blood cells (Zanella et al.
1980). Nevertheless, increased total glutathione levels were
observed in cortical and striatal mitochondria of R6/2
mice (Choo et al. 2005). Postmortem oxidation of GSH
to GSSG is a key factor that may explain such variability
between published studies.
Fig. 5 Levels of glutamate and
cystathionine in mice. Brain
samples of 7-month-old WT and
R6/1 mice were processed and
compared with authentic
standards. a Glutamate, and b
cystathionine were quantified
from striatum, cortex, and
cerebellum areas. The data is
represented as a mean relative
intensity ± SE. *p < 0.05
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Conclusions
The existence of oxidative stress in affected areas of HD pa-
tients and animal models is widely assumed. Although it is not
completely understood how mHtt causes this stress, a toxic
gain of function is well accepted. It is clear that mHtt expres-
sion results in increased levels of oxidatively damaged pro-
teins in specific areas of the HD-affected brain (Sorolla et al.
2012). Oxidation of enzymes like PDXK might explain the
decreased levels of this enzyme observed in human and mu-
rine HD samples. In agreement, pyridoxal levels were in-
creased both in striatum and cortex and PLP was found to be
reduced in striatum. The fact that in cerebellum, a less affected
area in HD, differences were not detected underline their rel-
evance in HD. Decreased PLP-dependent metabolism would
affect important pathways known to be altered in HD, includ-
ing synthesis of neurotransmitters like GABA and GSH me-
tabolism. In this context, treatment with PLP, the active form
of vitamin B6 (instead of pyridoxine or pyridoxal), should be
considered for evaluation as a potential therapy.
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